Literature DB >> 7530651

Skeletal muscle cell-derived insulin-like growth factor (IGF) binding proteins inhibit IGF-I-induced myogenesis in rat L6E9 cells.

L A Silverman1, Z Q Cheng, D Hsiao, S M Rosenthal.   

Abstract

The insulin-like growth factors (IGFs) stimulate the differentiation of skeletal muscle cells. IGF binding proteins (IGFBPs), which are expressed by skeletal muscle cells, may enhance or inhibit IGF actions. To explore the role of skeletal muscle-derived IGFBPs in IGF-induced myogenesis, we compared the differentiation-inducing effects of IGF-I and des(1-3)IGF-I in rat L6E9 skeletal myoblasts. Des(1-3)IGF-I is a naturally occurring IGF-I analog with markedly reduced affinity for IGFBPs but with an affinity for the IGF-I receptor that is comparable to that for native IGF-I. We find that rat L6E9 cells produce principally IGFBP-4 and BP-6, with a minor component of IGFBP-5. Both IGFBP-4 and BP-6 accumulate during differentiation and increase further in response to IGF-I or des(1-3)IGF-I treatment. We find that an IGF-I analog with reduced affinity for IGFBPs is significantly more potent than native IGF-I in stimulating myogenesis (as assessed by myogenin messenger RNA abundance and muscle creatine kinase activity), indicating that IGFBPs expressed by skeletal muscle cells inhibit differentiation induced by IGF-I. In view of the relative abundance of IGFBP-4, its relatively high affinity for IGF-I and the low affinity of IGFBP-6 for IGF-I, it is likely that the inhibitory effect of rat skeletal muscle-derived IGFBPs on IGF-I-induced myogenesis is mediated principally by IGFBP-4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530651     DOI: 10.1210/endo.136.2.7530651

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  The influence of skeletal muscle on systemic aging and lifespan.

Authors:  Fabio Demontis; Rosanna Piccirillo; Alfred L Goldberg; Norbert Perrimon
Journal:  Aging Cell       Date:  2013-07-17       Impact factor: 9.304

2.  Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts.

Authors:  S M Rosenthal; Z Q Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

3.  Tissue specific and cyclic expression of insulin-like growth factor binding proteins-1,-2,-3,-4,-5,-6 in the rat oviduct.

Authors:  G F Erickson; M R Girvigian; A R Sadighian; A Nakatani; N Ling; S Shimasaki
Journal:  Endocrine       Date:  1995-09       Impact factor: 3.633

4.  Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors.

Authors:  E Long; H T Huynh; X Zhao
Journal:  Endocrine       Date:  1998-10       Impact factor: 3.925

5.  Insulin-Like Growth Factor Binding Protein-6 Alters Skeletal Muscle Differentiation of Human Mesenchymal Stem Cells.

Authors:  Doaa Aboalola; Victor K M Han
Journal:  Stem Cells Int       Date:  2017-09-14       Impact factor: 5.443

Review 6.  Drosophila exercise, an emerging model bridging the fields of exercise and aging in human.

Authors:  Meng Ding; Hongyu Li; Lan Zheng
Journal:  Front Cell Dev Biol       Date:  2022-09-09

7.  Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.

Authors:  P L James; C E Stewart; P Rotwein
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

8.  Different Effects of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-2 on Myogenic Differentiation of Human Mesenchymal Stem Cells.

Authors:  Doaa Aboalola; Victor K M Han
Journal:  Stem Cells Int       Date:  2017-12-14       Impact factor: 5.443

9.  Acquisition of an oncogenic fusion protein is sufficient to globally alter the landscape of miRNA expression to inhibit myogenic differentiation.

Authors:  Jacob M Loupe; Patrick J Miller; Judy S Crabtree; Jovanny Zabaleta; Andrew D Hollenbach
Journal:  Oncotarget       Date:  2017-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.